Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study
Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA i...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Manes, Marta [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
4 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Parkinsonism & related disorders - Aral, Efecan ELSEVIER, 2022, official journal of the World Federation of Neurology Research Committee on Parkinsonism and Related Disorders, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:63 ; year:2019 ; pages:191-194 ; extent:4 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.parkreldis.2019.02.040 |
|---|
| Katalog-ID: |
ELV047466804 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV047466804 | ||
| 003 | DE-627 | ||
| 005 | 20230624134949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.parkreldis.2019.02.040 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000703.pica |
| 035 | |a (DE-627)ELV047466804 | ||
| 035 | |a (ELSEVIER)S1353-8020(19)30085-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 42.13 |2 bkl | ||
| 084 | |a 44.33 |2 bkl | ||
| 100 | 1 | |a Manes, Marta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study |
| 264 | 1 | |c 2019 | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA in SCA38 by a 2-year open label extension study. | ||
| 650 | 7 | |a Cerebellum |2 Elsevier | |
| 650 | 7 | |a Docosahexaenoic acid (DHA) |2 Elsevier | |
| 650 | 7 | |a Ataxia |2 Elsevier | |
| 650 | 7 | |a Clinical trial |2 Elsevier | |
| 650 | 7 | |a Spinocerebellar ataxia 38 (SCA38) |2 Elsevier | |
| 700 | 1 | |a Alberici, Antonella |4 oth | |
| 700 | 1 | |a Di Gregorio, Eleonora |4 oth | |
| 700 | 1 | |a Boccone, Loredana |4 oth | |
| 700 | 1 | |a Premi, Enrico |4 oth | |
| 700 | 1 | |a Mitro, Nico |4 oth | |
| 700 | 1 | |a Pasolini, Maria Pia |4 oth | |
| 700 | 1 | |a Pani, Claudia |4 oth | |
| 700 | 1 | |a Paghera, Barbara |4 oth | |
| 700 | 1 | |a Orsi, Laura |4 oth | |
| 700 | 1 | |a Costanzi, Chiara |4 oth | |
| 700 | 1 | |a Ferrero, Marta |4 oth | |
| 700 | 1 | |a Tempia, Filippo |4 oth | |
| 700 | 1 | |a Caruso, Donatella |4 oth | |
| 700 | 1 | |a Padovani, Alessando |4 oth | |
| 700 | 1 | |a Brusco, Alfredo |4 oth | |
| 700 | 1 | |a Borroni, Barbara |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Aral, Efecan ELSEVIER |t Parkinsonism & related disorders |d 2022 |d official journal of the World Federation of Neurology Research Committee on Parkinsonism and Related Disorders |g Amsterdam [u.a.] |w (DE-627)ELV009218491 |
| 773 | 1 | 8 | |g volume:63 |g year:2019 |g pages:191-194 |g extent:4 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.parkreldis.2019.02.040 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 42.13 |j Molekularbiologie |q VZ |
| 936 | b | k | |a 44.33 |j Physiologische Chemie |q VZ |
| 951 | |a AR | ||
| 952 | |d 63 |j 2019 |h 191-194 |g 4 | ||
| author_variant |
m m mm |
|---|---|
| matchkey_str |
manesmartaalbericiantonelladigregorioele:2019----:ogemfiayfooaeaniaidaosioeeelrtxa8c3tete |
| hierarchy_sort_str |
2019 |
| bklnumber |
42.13 44.33 |
| publishDate |
2019 |
| allfields |
10.1016/j.parkreldis.2019.02.040 doi GBV00000000000703.pica (DE-627)ELV047466804 (ELSEVIER)S1353-8020(19)30085-9 DE-627 ger DE-627 rakwb eng 610 VZ 42.13 bkl 44.33 bkl Manes, Marta verfasserin aut Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study 2019 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA in SCA38 by a 2-year open label extension study. Cerebellum Elsevier Docosahexaenoic acid (DHA) Elsevier Ataxia Elsevier Clinical trial Elsevier Spinocerebellar ataxia 38 (SCA38) Elsevier Alberici, Antonella oth Di Gregorio, Eleonora oth Boccone, Loredana oth Premi, Enrico oth Mitro, Nico oth Pasolini, Maria Pia oth Pani, Claudia oth Paghera, Barbara oth Orsi, Laura oth Costanzi, Chiara oth Ferrero, Marta oth Tempia, Filippo oth Caruso, Donatella oth Padovani, Alessando oth Brusco, Alfredo oth Borroni, Barbara oth Enthalten in Elsevier Science Aral, Efecan ELSEVIER Parkinsonism & related disorders 2022 official journal of the World Federation of Neurology Research Committee on Parkinsonism and Related Disorders Amsterdam [u.a.] (DE-627)ELV009218491 volume:63 year:2019 pages:191-194 extent:4 https://doi.org/10.1016/j.parkreldis.2019.02.040 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 42.13 Molekularbiologie VZ 44.33 Physiologische Chemie VZ AR 63 2019 191-194 4 |
| spelling |
10.1016/j.parkreldis.2019.02.040 doi GBV00000000000703.pica (DE-627)ELV047466804 (ELSEVIER)S1353-8020(19)30085-9 DE-627 ger DE-627 rakwb eng 610 VZ 42.13 bkl 44.33 bkl Manes, Marta verfasserin aut Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study 2019 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA in SCA38 by a 2-year open label extension study. Cerebellum Elsevier Docosahexaenoic acid (DHA) Elsevier Ataxia Elsevier Clinical trial Elsevier Spinocerebellar ataxia 38 (SCA38) Elsevier Alberici, Antonella oth Di Gregorio, Eleonora oth Boccone, Loredana oth Premi, Enrico oth Mitro, Nico oth Pasolini, Maria Pia oth Pani, Claudia oth Paghera, Barbara oth Orsi, Laura oth Costanzi, Chiara oth Ferrero, Marta oth Tempia, Filippo oth Caruso, Donatella oth Padovani, Alessando oth Brusco, Alfredo oth Borroni, Barbara oth Enthalten in Elsevier Science Aral, Efecan ELSEVIER Parkinsonism & related disorders 2022 official journal of the World Federation of Neurology Research Committee on Parkinsonism and Related Disorders Amsterdam [u.a.] (DE-627)ELV009218491 volume:63 year:2019 pages:191-194 extent:4 https://doi.org/10.1016/j.parkreldis.2019.02.040 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 42.13 Molekularbiologie VZ 44.33 Physiologische Chemie VZ AR 63 2019 191-194 4 |
| allfields_unstemmed |
10.1016/j.parkreldis.2019.02.040 doi GBV00000000000703.pica (DE-627)ELV047466804 (ELSEVIER)S1353-8020(19)30085-9 DE-627 ger DE-627 rakwb eng 610 VZ 42.13 bkl 44.33 bkl Manes, Marta verfasserin aut Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study 2019 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA in SCA38 by a 2-year open label extension study. Cerebellum Elsevier Docosahexaenoic acid (DHA) Elsevier Ataxia Elsevier Clinical trial Elsevier Spinocerebellar ataxia 38 (SCA38) Elsevier Alberici, Antonella oth Di Gregorio, Eleonora oth Boccone, Loredana oth Premi, Enrico oth Mitro, Nico oth Pasolini, Maria Pia oth Pani, Claudia oth Paghera, Barbara oth Orsi, Laura oth Costanzi, Chiara oth Ferrero, Marta oth Tempia, Filippo oth Caruso, Donatella oth Padovani, Alessando oth Brusco, Alfredo oth Borroni, Barbara oth Enthalten in Elsevier Science Aral, Efecan ELSEVIER Parkinsonism & related disorders 2022 official journal of the World Federation of Neurology Research Committee on Parkinsonism and Related Disorders Amsterdam [u.a.] (DE-627)ELV009218491 volume:63 year:2019 pages:191-194 extent:4 https://doi.org/10.1016/j.parkreldis.2019.02.040 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 42.13 Molekularbiologie VZ 44.33 Physiologische Chemie VZ AR 63 2019 191-194 4 |
| allfieldsGer |
10.1016/j.parkreldis.2019.02.040 doi GBV00000000000703.pica (DE-627)ELV047466804 (ELSEVIER)S1353-8020(19)30085-9 DE-627 ger DE-627 rakwb eng 610 VZ 42.13 bkl 44.33 bkl Manes, Marta verfasserin aut Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study 2019 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA in SCA38 by a 2-year open label extension study. Cerebellum Elsevier Docosahexaenoic acid (DHA) Elsevier Ataxia Elsevier Clinical trial Elsevier Spinocerebellar ataxia 38 (SCA38) Elsevier Alberici, Antonella oth Di Gregorio, Eleonora oth Boccone, Loredana oth Premi, Enrico oth Mitro, Nico oth Pasolini, Maria Pia oth Pani, Claudia oth Paghera, Barbara oth Orsi, Laura oth Costanzi, Chiara oth Ferrero, Marta oth Tempia, Filippo oth Caruso, Donatella oth Padovani, Alessando oth Brusco, Alfredo oth Borroni, Barbara oth Enthalten in Elsevier Science Aral, Efecan ELSEVIER Parkinsonism & related disorders 2022 official journal of the World Federation of Neurology Research Committee on Parkinsonism and Related Disorders Amsterdam [u.a.] (DE-627)ELV009218491 volume:63 year:2019 pages:191-194 extent:4 https://doi.org/10.1016/j.parkreldis.2019.02.040 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 42.13 Molekularbiologie VZ 44.33 Physiologische Chemie VZ AR 63 2019 191-194 4 |
| allfieldsSound |
10.1016/j.parkreldis.2019.02.040 doi GBV00000000000703.pica (DE-627)ELV047466804 (ELSEVIER)S1353-8020(19)30085-9 DE-627 ger DE-627 rakwb eng 610 VZ 42.13 bkl 44.33 bkl Manes, Marta verfasserin aut Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study 2019 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA in SCA38 by a 2-year open label extension study. Cerebellum Elsevier Docosahexaenoic acid (DHA) Elsevier Ataxia Elsevier Clinical trial Elsevier Spinocerebellar ataxia 38 (SCA38) Elsevier Alberici, Antonella oth Di Gregorio, Eleonora oth Boccone, Loredana oth Premi, Enrico oth Mitro, Nico oth Pasolini, Maria Pia oth Pani, Claudia oth Paghera, Barbara oth Orsi, Laura oth Costanzi, Chiara oth Ferrero, Marta oth Tempia, Filippo oth Caruso, Donatella oth Padovani, Alessando oth Brusco, Alfredo oth Borroni, Barbara oth Enthalten in Elsevier Science Aral, Efecan ELSEVIER Parkinsonism & related disorders 2022 official journal of the World Federation of Neurology Research Committee on Parkinsonism and Related Disorders Amsterdam [u.a.] (DE-627)ELV009218491 volume:63 year:2019 pages:191-194 extent:4 https://doi.org/10.1016/j.parkreldis.2019.02.040 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 42.13 Molekularbiologie VZ 44.33 Physiologische Chemie VZ AR 63 2019 191-194 4 |
| language |
English |
| source |
Enthalten in Parkinsonism & related disorders Amsterdam [u.a.] volume:63 year:2019 pages:191-194 extent:4 |
| sourceStr |
Enthalten in Parkinsonism & related disorders Amsterdam [u.a.] volume:63 year:2019 pages:191-194 extent:4 |
| format_phy_str_mv |
Article |
| bklname |
Molekularbiologie Physiologische Chemie |
| institution |
findex.gbv.de |
| topic_facet |
Cerebellum Docosahexaenoic acid (DHA) Ataxia Clinical trial Spinocerebellar ataxia 38 (SCA38) |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Parkinsonism & related disorders |
| authorswithroles_txt_mv |
Manes, Marta @@aut@@ Alberici, Antonella @@oth@@ Di Gregorio, Eleonora @@oth@@ Boccone, Loredana @@oth@@ Premi, Enrico @@oth@@ Mitro, Nico @@oth@@ Pasolini, Maria Pia @@oth@@ Pani, Claudia @@oth@@ Paghera, Barbara @@oth@@ Orsi, Laura @@oth@@ Costanzi, Chiara @@oth@@ Ferrero, Marta @@oth@@ Tempia, Filippo @@oth@@ Caruso, Donatella @@oth@@ Padovani, Alessando @@oth@@ Brusco, Alfredo @@oth@@ Borroni, Barbara @@oth@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV009218491 |
| dewey-sort |
3610 |
| id |
ELV047466804 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047466804</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624134949.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.parkreldis.2019.02.040</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000703.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047466804</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1353-8020(19)30085-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.33</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Manes, Marta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA in SCA38 by a 2-year open label extension study.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cerebellum</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Docosahexaenoic acid (DHA)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ataxia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Spinocerebellar ataxia 38 (SCA38)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alberici, Antonella</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Di Gregorio, Eleonora</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boccone, Loredana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Premi, Enrico</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mitro, Nico</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pasolini, Maria Pia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pani, Claudia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paghera, Barbara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Orsi, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Costanzi, Chiara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferrero, Marta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tempia, Filippo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Caruso, Donatella</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Padovani, Alessando</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brusco, Alfredo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borroni, Barbara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Aral, Efecan ELSEVIER</subfield><subfield code="t">Parkinsonism & related disorders</subfield><subfield code="d">2022</subfield><subfield code="d">official journal of the World Federation of Neurology Research Committee on Parkinsonism and Related Disorders</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV009218491</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:63</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:191-194</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.parkreldis.2019.02.040</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.13</subfield><subfield code="j">Molekularbiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.33</subfield><subfield code="j">Physiologische Chemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">63</subfield><subfield code="j">2019</subfield><subfield code="h">191-194</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| author |
Manes, Marta |
| spellingShingle |
Manes, Marta ddc 610 bkl 42.13 bkl 44.33 Elsevier Cerebellum Elsevier Docosahexaenoic acid (DHA) Elsevier Ataxia Elsevier Clinical trial Elsevier Spinocerebellar ataxia 38 (SCA38) Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study |
| authorStr |
Manes, Marta |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV009218491 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 42.13 bkl 44.33 bkl Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study Cerebellum Elsevier Docosahexaenoic acid (DHA) Elsevier Ataxia Elsevier Clinical trial Elsevier Spinocerebellar ataxia 38 (SCA38) Elsevier |
| topic |
ddc 610 bkl 42.13 bkl 44.33 Elsevier Cerebellum Elsevier Docosahexaenoic acid (DHA) Elsevier Ataxia Elsevier Clinical trial Elsevier Spinocerebellar ataxia 38 (SCA38) |
| topic_unstemmed |
ddc 610 bkl 42.13 bkl 44.33 Elsevier Cerebellum Elsevier Docosahexaenoic acid (DHA) Elsevier Ataxia Elsevier Clinical trial Elsevier Spinocerebellar ataxia 38 (SCA38) |
| topic_browse |
ddc 610 bkl 42.13 bkl 44.33 Elsevier Cerebellum Elsevier Docosahexaenoic acid (DHA) Elsevier Ataxia Elsevier Clinical trial Elsevier Spinocerebellar ataxia 38 (SCA38) |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a a aa g e d ge ged l b lb e p ep n m nm m p p mp mpp c p cp b p bp l o lo c c cc m f mf f t ft d c dc a p ap a b ab b b bb |
| hierarchy_parent_title |
Parkinsonism & related disorders |
| hierarchy_parent_id |
ELV009218491 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Parkinsonism & related disorders |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV009218491 |
| title |
Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study |
| ctrlnum |
(DE-627)ELV047466804 (ELSEVIER)S1353-8020(19)30085-9 |
| title_full |
Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study |
| author_sort |
Manes, Marta |
| journal |
Parkinsonism & related disorders |
| journalStr |
Parkinsonism & related disorders |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
191 |
| author_browse |
Manes, Marta |
| container_volume |
63 |
| physical |
4 |
| class |
610 VZ 42.13 bkl 44.33 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Manes, Marta |
| doi_str_mv |
10.1016/j.parkreldis.2019.02.040 |
| dewey-full |
610 |
| title_sort |
long-term efficacy of docosahexaenoic acid (dha) for spinocerebellar ataxia 38 (sca38) treatment: an open label extension study |
| title_auth |
Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study |
| abstract |
Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA in SCA38 by a 2-year open label extension study. |
| abstractGer |
Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA in SCA38 by a 2-year open label extension study. |
| abstract_unstemmed |
Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA in SCA38 by a 2-year open label extension study. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study |
| url |
https://doi.org/10.1016/j.parkreldis.2019.02.040 |
| remote_bool |
true |
| author2 |
Alberici, Antonella Di Gregorio, Eleonora Boccone, Loredana Premi, Enrico Mitro, Nico Pasolini, Maria Pia Pani, Claudia Paghera, Barbara Orsi, Laura Costanzi, Chiara Ferrero, Marta Tempia, Filippo Caruso, Donatella Padovani, Alessando Brusco, Alfredo Borroni, Barbara |
| author2Str |
Alberici, Antonella Di Gregorio, Eleonora Boccone, Loredana Premi, Enrico Mitro, Nico Pasolini, Maria Pia Pani, Claudia Paghera, Barbara Orsi, Laura Costanzi, Chiara Ferrero, Marta Tempia, Filippo Caruso, Donatella Padovani, Alessando Brusco, Alfredo Borroni, Barbara |
| ppnlink |
ELV009218491 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.parkreldis.2019.02.040 |
| up_date |
2024-07-06T22:57:37.430Z |
| _version_ |
1803872273622368256 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047466804</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624134949.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.parkreldis.2019.02.040</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000703.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047466804</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1353-8020(19)30085-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.33</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Manes, Marta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Long-term efficacy of docosahexaenoic acid (DHA) for Spinocerebellar Ataxia 38 (SCA38) treatment: An open label extension study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Spinocerebellar Ataxia 38 (SCA38) is caused by ELOVL5 gene mutation, with significant reduction of serum docosahexaenoic acid (DHA) levels. DHA supplementation has been proven effective at short-term follow-up. In the present paper, we evaluated long-term safety and efficacy of 600 mg/day oral DHA in SCA38 by a 2-year open label extension study.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cerebellum</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Docosahexaenoic acid (DHA)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ataxia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Spinocerebellar ataxia 38 (SCA38)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alberici, Antonella</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Di Gregorio, Eleonora</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boccone, Loredana</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Premi, Enrico</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mitro, Nico</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pasolini, Maria Pia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pani, Claudia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paghera, Barbara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Orsi, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Costanzi, Chiara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ferrero, Marta</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tempia, Filippo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Caruso, Donatella</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Padovani, Alessando</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brusco, Alfredo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Borroni, Barbara</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Aral, Efecan ELSEVIER</subfield><subfield code="t">Parkinsonism & related disorders</subfield><subfield code="d">2022</subfield><subfield code="d">official journal of the World Federation of Neurology Research Committee on Parkinsonism and Related Disorders</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV009218491</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:63</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:191-194</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.parkreldis.2019.02.040</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.13</subfield><subfield code="j">Molekularbiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.33</subfield><subfield code="j">Physiologische Chemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">63</subfield><subfield code="j">2019</subfield><subfield code="h">191-194</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| score |
7.399912 |